Hematology-Oncology News:  <ol> <li>Radiotherapy planning scans reveal breast cancer patients’ CVD risk (<a href= "https://bit.ly/2FeoJiH">https://bit.ly/2FeoJiH</a>) </li> <li>FDA OKs combination immunotherapy for first-line mesothelioma treatment (<a href= "https://bit.ly/2Ff77mS">https://bit.ly/2Ff77mS</a>) </li> <li>Apatinib plus gefitinib: Better PFS but more toxicity (<a href= "https://bit.ly/34IyVsn">https://bit.ly/34IyVsn</a>) </li> <li>Atezolizumab strikes out in ovarian cancer (<a href= "https://bit.ly/3iPjXG1">https://bit.ly/3iPjXG1</a>) </li> </ol> Email Blood & Cancer at <a href= "mailto:podcasts@mdedge.com">podcasts@mdedge.com</a> and learn more at <a href= "https://www.mdedge.com/podcasts/blood-cancer">https://www.mdedge.com/podcasts/blood-cancer</a>

TERAVOLT registry sheds light on characteristics, treatment, and outcomes of patients with thoracic cancers and COVID-19

The official podcast feed of MDedge Hematology-Oncology, part of the Medscape Professional Network. On Thursdays, Dr. David Henry interviews key opinion leaders and rising stars in hematology and oncology. The information in this podcast is provided for informational and educational purposes only.